The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is a phase IV, open label, prospective, one phase pharmacokinetic and observational
study.
Twenty HIV-1 infected subjects will be recruited, subjects will switch antiretroviral therapy
to:
- tenofovir/emtricitabine 245/200 mg daily (Truvada™) plus
- raltegravir 400 mg twice daily On day 28, all subjects will attend for an intensive 24
hour pharmacokinetic visit.